Cumberland Pharmaceuticals (CPIX) Fundamental Analysis: Revenue, Earnings & Valuation

7.22 / 10

Outperform

Fundamental analysis rates CPIX as Outperform with a 7.2/10 score. Strengths include high inventory turnover, low cost‑of‑sales ratio, strong asset‑MV and PB‑ROE differentials, and robust revenue growth (17.6% YoY). Weaknesses are low accounts‑receivable turnover and negative income‑tax‑to‑profit ratio.

Analysis Checks(8/10)

Revenue-MV

Value0.04

Score2/3

Weight22.63%

1M Return6.87%

Total operating revenue (YoY growth rate %)

Value17.57

Score2/3

Weight1.42%

1M Return0.58%

Inventory turnover ratio

Value1.30

Score2/3

Weight-1.68%

1M Return-0.66%

Accounts receivable turnover ratio

Value2.82

Score1/3

Weight-3.78%

1M Return-1.57%

PB-ROE

Value-0.29

Score3/3

Weight38.61%

1M Return12.56%

Income tax / Total profit (%)

Value-1.43

Score1/3

Weight-1.37%

1M Return-0.59%

Fixed assets turnover ratio

Value5.36

Score3/3

Weight2.00%

1M Return0.79%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-1.69%

1M Return-0.73%

Cost of sales ratio (%)

Value16.50

Score3/3

Weight2.11%

1M Return0.79%

Asset-MV

Value-0.55

Score3/3

Weight41.76%

1M Return13.09%

Is CPIX fundamentally strong?

CPIX scores 7.22/10 on fundamentals and holds a Discounted valuation at present. Backed by its -12.05% ROE, -6.43% net margin, -17.67 P/E ratio, 2.04 P/B ratio, and 58.70% earnings growth, these metrics solidify its Outperform investment rating.